Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte-predominant cells in NLPHL are consistently positive for CD20, but do not express CD30. The clinical course of NLPHL is indolent in the majority of cases. Most patients present with early-stage disease at the initial diagnosis. First-line treatment of stage IA NLPHL usually consists of limited-field radiotherapy alone. Patients with early-stage NLPHL other than stage IA and intermediate-stage disease mostly receive combined-modality treatment, whereas individuals with advanced NLPHL are treated with chemotherapy alone. In relapsed NLPHL, conventional chemotherapy, anti-CD20 antibodies, and radiotherapy represent active treatment modalities. Only patients with poor-risk characteristics such as early disease recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy and autologous stem cell transplantation. The overall and relative survival of patients with NLPHL is excellent as indicated by a low excess mortality compared with the general population. This article discusses treatment options for patients with NLPHL and factors that influence the choice of therapy on the basis of the available data and 2 clinical cases.

REFERENCES

1.
Eichenauer
DA
,
Engert
A
.
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
.
Hematology Am Soc Hematol Educ Program
.
2017
;
2017
:
324
-
328
.
2.
Nogová
L
,
Reineke
T
,
Brillant
C
, et al;
German Hodgkin Study Group
.
Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group
.
J Clin Oncol
.
2008
;
26
(
3
):
434
-
439
.
3.
Lazarovici
J
,
Dartigues
P
,
Brice
P
, et al
.
Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study
.
Haematologica
.
2015
;
100
(
12
):
1579
-
1586
.
4.
Hartmann
S
,
Eichenauer
DA
.
Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma
.
Pathology
.
2020
;
52
(
1
):
142
-
153
.
5.
Fan
Z
,
Natkunam
Y
,
Bair
E
,
Tibshirani
R
,
Warnke
RA
.
Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation
.
Am J Surg Pathol
.
2003
;
27
(
10
):
1346
-
1356
.
6.
Hartmann
S
,
Eichenauer
DA
,
Plütschow
A
, et al
.
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
.
Blood
.
2013
;
122
(
26
):
4246
-
4252, quiz 4292
.
7.
Hartmann
S
,
Plütschow
A
,
Mottok
A
, et al
.
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
.
Am J Hematol
.
2019
;
94
(
11
):
1208
-
1213
.
8.
Eichenauer
DA
,
Plütschow
A
,
Fuchs
M
, et al
.
Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group
.
J Clin Oncol
.
2020
;
38
(
7
):
698
-
705
.
9.
Eichenauer
DA
,
Plütschow
A
,
Schröder
L
, et al
.
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
.
Blood
.
2018
;
132
(
14
):
1519
-
1525
.
10.
Al-Mansour
M
,
Connors
JM
,
Gascoyne
RD
,
Skinnider
B
,
Savage
KJ
.
Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma
.
J Clin Oncol
.
2010
;
28
(
5
):
793
-
799
.
11.
Posthuma
HLA
,
Zijlstra
JM
,
Visser
O
,
Lugtenburg
PJ
,
Kersten
MJ
,
Dinmohamed
AG
.
Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016
.
Br J Haematol
.
2020
;
189
(
1
):
117
-
121
.
12.
Eichenauer
DA
,
Plütschow
A
,
Fuchs
M
, et al
.
Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
.
J Clin Oncol
.
2015
;
33
(
26
):
2857
-
2862
.
13.
Eichenauer
DA
,
Fuchs
M
,
Pluetschow
A
, et al
.
Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
.
Blood
.
2011
;
118
(
16
):
4363
-
4365
.
14.
Eichenauer
DA
,
Goergen
H
,
Plütschow
A
, et al
.
Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group
.
Leukemia
.
2016
;
30
(
6
):
1425
-
1427
.
15.
Behringer
K
,
Goergen
H
,
Hitz
F
, et al;
Arbeitsgemeinschaft Medikamentöse Tumortherapie
.
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
.
Lancet
.
2015
;
385
(
9976
):
1418
-
1427
.
16.
Nogová
L
,
Reineke
T
,
Eich
HT
, et al
.
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
.
Ann Oncol
.
2005
;
16
(
10
):
1683
-
1687
.
17.
Chen
RC
,
Chin
MS
,
Ng
AK
, et al
.
Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up
.
J Clin Oncol
.
2010
;
28
(
1
):
136
-
141
.
18.
Pinnix
CC
,
Milgrom
SA
,
Cheah
CY
, et al
.
Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma
.
Blood Adv
.
2019
;
3
(
9
):
1356
-
1367
.
19.
Eichenauer
DA
,
Plütschow
A
,
Fuchs
M
, et al
.
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
.
Leukemia
.
2020
;
34
(
3
):
953
-
956
.
20.
Appel
BE
,
Chen
L
,
Buxton
AB
, et al
.
Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children’s Oncology Group
.
J Clin Oncol
.
2016
;
34
(
20
):
2372
-
2379
.
21.
Savage
KJ
,
Skinnider
B
,
Al-Mansour
M
,
Sehn
LH
,
Gascoyne
RD
,
Connors
JM
.
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
.
Blood
.
2011
;
118
(
17
):
4585
-
4590
.
22.
Garciaz
S
,
Harel
S
,
Amorim
S
,
Bouabdallah
R
,
Thieblemont
C
,
Brice
P
.
Rituximab-ABV(D) for patients with nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy
.
Br J Haematol
.
2016
;
175
(
4
):
735
-
737
.
23.
Cencini
E
,
Fabbri
A
,
Bocchia
M
.
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma
.
Br J Haematol
.
2017
;
176
(
5
):
831
-
833
.
24.
Wilson
MR
,
Bagguley
T
,
Smith
A
, et al
.
Frontline management of nodular lymphocyte predominant Hodgkin lymphoma—a retrospective UK multicentre study
.
Br J Haematol
.
2019
;
186
(
6
):
e214
-
e217
.
25.
Prusila
REI
,
Haapasaari
KM
,
Marin
K
, et al
.
R-bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma
.
Acta Oncol
.
2018
;
57
(
9
):
1265
-
1267
.
26.
Haas
RL
,
Girinsky
T
,
Aleman
BM
,
Henry-Amar
M
,
de Boer
JP
,
de Jong
D
.
Low-dose involved-field radiotherapy as alternative treatment of nodular lymphocyte predominance Hodgkin’s lymphoma
.
Int J Radiat Oncol Biol Phys
.
2009
;
74
(
4
):
1199
-
1202
.
27.
Binkley
MS
,
Rauf
MS
,
Milgrom
SA
, et al
.
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
.
Blood
.
2020
;
135
(
26
):
2365
-
2374
.
28.
Eichenauer
DA
,
Kreissl
S
,
Bühnen
I
, et al
PET-2-guided escalated BEACOPP for patients with advanced nodular lymphocyte-predominant HODGKIN lymphoma: an analysis from the German Hodgkin Study Group [abstract]. Hemasphere.
2020
. Abstract S220.
29.
Diehl
V
,
Franklin
J
,
Pfreundschuh
M
, et al;
German Hodgkin’s Lymphoma Study Group
.
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease [published correction appears in N Engl J Med. 2005;353(7):744]
.
N Engl J Med
.
2003
;
348
(
24
):
2386
-
2395
.
30.
Eichenauer
DA
,
Thielen
I
,
Haverkamp
H
, et al
.
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
.
Blood
.
2014
;
123
(
11
):
1658
-
1664
.
31.
Behringer
K
,
Mueller
H
,
Goergen
H
, et al
.
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials
.
J Clin Oncol
.
2013
;
31
(
2
):
231
-
239
.
32.
Eichenauer
DA
,
Becker
I
,
Monsef
I
, et al
.
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
.
Haematologica
.
2017
;
102
(
10
):
1748
-
1757
.
33.
Xing
KH
,
Connors
JM
,
Lai
A
, et al
.
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis
.
Blood
.
2014
;
123
(
23
):
3567
-
3573
.
34.
Fanale
MA
,
Cheah
CY
,
Rich
A
, et al
.
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma
.
Blood
.
2017
;
130
(
4
):
472
-
477
.
35.
Advani
RH
,
Horning
SJ
,
Hoppe
RT
, et al
.
Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma
.
J Clin Oncol
.
2014
;
32
(
9
):
912
-
918
.
36.
Borchmann
P
,
Goergen
H
,
Kobe
C
, et al
.
PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
.
Lancet
.
2018
;
390
(
10114
):
2790
-
2802
.
37.
Canellos
GP
,
Mauch
P
.
What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin’s lymphoma?
J Clin Oncol
.
2010
;
28
(
1
):
e8
.
38.
Borchmann
S
,
Joffe
E
,
Moskowitz
CH
, et al
.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
.
Blood
.
2019
;
133
(
20
):
2121
-
2129
.
39.
Schulz
H
,
Rehwald
U
,
Morschhauser
F
, et al
.
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
.
Blood
.
2008
;
111
(
1
):
109
-
111
.
40.
Akhtar
S
,
Montoto
S
,
Boumendil
A
, et al
.
High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: a retrospective study by the European Society for Blood and Marrow Transplantation-Lymphoma Working Party
.
Am J Hematol
.
2018
;
93
(
1
):
40
-
46
.
41.
Karuturi
M
,
Hosing
C
,
Fanale
M
, et al
.
High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma
.
Biol Blood Marrow Transplant
.
2013
;
19
(
6
):
991
-
994
.
42.
Biasoli
I
,
Stamatoullas
A
,
Meignin
V
, et al
.
Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group
.
Cancer
.
2010
;
116
(
3
):
631
-
639
.
43.
Hoppe
RT
,
Advani
RH
,
Ai
WZ
, et al
.
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
.
J Natl Compr Canc Netw
.
2012
;
10
(
5
):
589
-
597
.
You do not currently have access to this content.

Sign in via your Institution

Sign In